Repair Biotechnologies has filed a notice of an exempt offering of securities to raise $8,625,520.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Repair Biotechnologies is raising $8,625,520.00 in new funding. Sources indicate that as part of senior management Chairman, Bill Cherman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Repair Biotechnologies
Repair Biotechnologies is a preclinical biotechnology company focused on developing drugs for cholesterol and aging-related diseases. Our first-in-class Cholesterol Degrading Platform (CDP) technology is aimed at reversing atherosclerosis, familial hypercholesterolemias, and other conditions in which excess or modified cholesterol drives pathology.
To learn more about Repair Biotechnologies, visit http://www.repairbiotechnologies.com/
Contact:
Bill Cherman, Chairman
315-299-2407
https://www.linkedin.com/in/bcherman/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.